Literature DB >> 22744304

[Diagnosis and therapy of axial spondyloarthritis including ankylosing spondylitis (Bechterew's disease)].

D Poddubnyy1, J Sieper.   

Abstract

The term axial spondyloarthritis covers patients with established structural changes visible on x-ray in sacroiliac joints and/or in the spine (classical ankylosing spondylitis) but also patients with non-radiographic axial spondyloarthritis in whom early inflammatory signs of the disease can only be visualized with magnetic resonance imaging (MRI). The MRI technique plays an important role in the diagnosis of this disease and an early diagnosis is normally based on a combination of clinical, laboratory and imaging parameters. Only non-steroidal anti-inflammatory drugs and TNF-α blockers are effective in the treatment of axial spondyloarthritis. Patients with short disease duration and elevated acute phase reactant levels demonstrate best therapy response and, therefore, should be closely followed-up and consistently treated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22744304     DOI: 10.1007/s00132-012-1926-7

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  28 in total

Review 1.  Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

Authors:  J Braun; X Baraliakos; J Listing; J Sieper
Journal:  Arthritis Rheum       Date:  2005-08

2.  Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside.

Authors:  M Rudwaleit; E Feldtkeller; J Sieper
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

3.  A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.

Authors:  Maxime Dougados; Bernard Combe; Jürgen Braun; Robert Landewé; Jean Sibilia; Alain Cantagrel; Antoine Feydy; Désirée van der Heijde; Véronique Leblanc; Isabelle Logeart
Journal:  Ann Rheum Dis       Date:  2010-05-28       Impact factor: 19.103

4.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

5.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.

Authors:  M Rudwaleit; R Landewé; D van der Heijde; J Listing; J Brandt; J Braun; R Burgos-Vargas; E Collantes-Estevez; J Davis; B Dijkmans; M Dougados; P Emery; I E van der Horst-Bruinsma; R Inman; M A Khan; M Leirisalo-Repo; S van der Linden; W P Maksymowych; H Mielants; I Olivieri; R Sturrock; K de Vlam; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

6.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

7.  Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.

Authors:  Martin Rudwaleit; Pascal Claudepierre; Paul Wordsworth; Eduardo Loza Cortina; Joachim Sieper; Martina Kron; Roberto Carcereri-De-Prati; Hartmut Kupper; Sonja Kary
Journal:  J Rheumatol       Date:  2009-02-27       Impact factor: 4.666

8.  MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

Authors:  M Rudwaleit; S Schwarzlose; E S Hilgert; J Listing; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2007-11-15       Impact factor: 19.103

9.  Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.

Authors:  J Sieper; T Klopsch; M Richter; A Kapelle; M Rudwaleit; S Schwank; E Regourd; M May
Journal:  Ann Rheum Dis       Date:  2007-07-06       Impact factor: 19.103

10.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

View more
  1 in total

Review 1.  [Surgical management of ankylosing spondylitis (Bechterew's disease)].

Authors:  H Allouch; M Shousha; H Böhm
Journal:  Z Rheumatol       Date:  2017-12       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.